Crossmark

Novel CDK2/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E)

Crossref DOI link: https://doi.org/10.1038/s41389-025-00574-1

Published Online: 2025-08-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mohiuddin, Md

Póvoa, Vanda

Fior, Rita

Sinicrope, Frank A. https://orcid.org/0000-0002-2907-1000
Funding

Funding for this research was provided by:

Mayo Clinic (P30 DK084567)
License Information

Text and Data Mining valid from 2025-08-06

Version of Record valid from 2025-08-06
More Information

Article History

Received: 8 April 2025

Revised: 11 July 2025

Accepted: 24 July 2025

First Online: 6 August 2025

Competing interests

: The authors declare no competing interests.

: All methods were performed in accordance with the relevant guidelines and regulations. In vivo experiments were performed using zebrafish (Danio rerio), which were handled according to European animal welfare Legislation, Directive 2010/63/EU (European Commission, 2016), DGAV-ORBEA 004166/0421/000/000/2020. No human research was conducted in this manuscript.

Document is current

Any future updates will be listed below